Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Evaluation of Multiple Assessment Modalities for the Detection and Characterisation of the Preclinical, Pre-symptomatic Stage of Neovascular Age-related Macular Degeneration
Authors not listed
Aston University · 2014
Abstract
Neovascular or wet age-related macular degeneration (ARMD) is a retinal disease and is the leading cause of sight loss in the over 50s; it constitutes a major public health problem which will have an increasingly large impact as the population ages, because sight loss has been associated with loss of independence, depression, social isolation, and falls.
Recent advances in medicine, and in particular the approval on behalf of the National Institute for Health and Clinical Excellence (NICE) for use of ranibizumab (Lucentis) in wet ARMD, have allowed this condition to be treated; however success is more likely when treatments occur at a very early stage.
Unfortunately the early stages of wet ARMD do not cause symptoms and most cases are diagnosed when irreversible retinal damage has already occurred.
In all stages of ARMD, even when no symptoms are present and non-invasive techniques currently used in routine clinical practice are not sufficiently sensitive to identify abnormalities, retinal function and possibly anatomy are abnormal.
This study will evaluate techniques that may be useful in flagging subjects with the "preclinical" stages of the disease. This may allow early preventative measures to be taken, in order to stop altogether the onset of blindness.
The study will focus mainly on colour contrast sensitivity, a simple but highly sensitive technique to assess retinal function, to establish if people with wet ARMD can be identified before symptoms develop. Other assessment modalities, evaluating either structure or function of the retina, will also be employed in selected individuals to establish if they may be used in the routine clinic; however it is already known that these modalities are not suitable for all individuals, as they are more demanding time-wise and concentration-wise, and therefore not universally suitable.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-15 MST
Cite this
APA
Anonymous. (2014). Evaluation of Multiple Assessment Modalities for the Detection and Characterisation of the Preclinical, Pre-symptomatic Stage of Neovascular Age-related Macular Degeneration. <em>Aston University</em>. https://clinicaltrials.gov/study/NCT02173496
Vancouver
Anonymous. Evaluation of Multiple Assessment Modalities for the Detection and Characterisation of the Preclinical, Pre-symptomatic Stage of Neovascular Age-related Macular Degeneration. Aston University. 2014.
BibTeX
@misc{anon2014Evalua,
title = {Evaluation of Multiple Assessment Modalities for the Detection and Characterisation of the Preclinical, Pre-symptomatic Stage of Neovascular Age-related Macular Degeneration},
author = {Anonymous},
journal = {Aston University},
year = {2014},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Health Service Executive, Ireland 2019
Open access · US-GOV
Dundrum Forensic Redevelopment Evaluation Study: D-FOREST Study.
Latin American Cooperative Oncology Group 2026
Open access · US-GOV
Validation of the G8 Screening Tool for Prognostic Assessment of Frailty and Early Mortality in Elderly Individuals With Cancer: Prospective Cohort Study in Brazil - CORALINE (LACOG 0625)
Universidad Nacional de Educación a Distancia 2015
Open access · US-GOV
Age-related Cognitive Decline: Effects of Video Game Training on Behavioral and Neuroimaging Measures of Attention and Memory
Getúlio Vargas University Hospital 2026
Open access · US-GOV
Use of Wearables for Identifying Factors Associated With Mild Cognitive Impairment and Early-Stage Alzheimer's Disease
Pfizer 2009
Open access · US-GOV
A Multicenter, Open Label, Multiple Dose, Parallel Group Investigation Of The Long-term Safety, Tolerability, Reactogenicity, Pharmacokinetics And Pharmacodynamics Of Aab-001 Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer's Disease
Brandeis University 2017
Open access · US-GOV